GEN-001

PreclinicalSmall molecule

GGenome & Company

GEN-001 is one of 40 small molecule programs targeting Locally-advanced Rectal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally-Advanced Rectal CancerUnknown status

Locally-Advanced Rectal CancerPreclinical

Unknown status

Competition

Competitive Landscape

49 competitors in Locally-Advanced Rectal Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

26 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

43 3

Beyfortus

BeiGene

Phase 3

9 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 5

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 6

FOLFOX

AstraZeneca

Phase 3

3 7

Camptosar

Pfizer

Phase 2

7 8

Avastin

Roche

Phase 2

6 9

Mfolfirinox

Incyte

Phase 3

2 10

Keytruda

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Unknown status·KKorean Cancer Study Group·N/A·NCT05079503·40 enrolled

Biliary Tract Cancer1 trial

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Terminated·GGenome & Company·Phase 2·NCT05998447·10 enrolled

Gastric Cancer1 trial

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Completed·GGenome & Company·Phase 2·NCT05419362·42 enrolled

Patients With Solid Tumors1 trial

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Completed·GGenome & Company·Phase 1·NCT04601402·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GEN-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GEN-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GEN-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genome & Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGenome & Company

GEN-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Biliary Tract Cancer1 trial

Gastric Cancer1 trial

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News